Computer‐Assisted Screening of Active Compounds in Traditional Chinese Medicine Targeting SNX10 as a Promising Treatment for Inflammatory Bowel Diseases
Basic & Clinical Pharmacology & Toxicology · 2025
DOI: 10.1111/bcpt.70098 ↗Kurz gefasst
Fachartikel in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, 2025. Verfasst von Yongpan An und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Xi'an People's Hospital (Xi'an Fourth Hospital), School of Life Sciences and Medicine, Northwest University, Xi'an, China. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Sorting Nexins, Drugs, Chinese Herbal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Youth Cultivation Program of Xi'an Municipal Healthcare Commission, Research Incubation Fund of Xi'an People's Hospital (Xi'an Fourth Hospital), General Research Program of Xi'an Municipal Health Commission.
Abstract (Originalsprache)
Inflammatory bowel diseases (IBD) are chronic and recurrent gastrointestinal disorders affecting millions worldwide, imposing significant social and economic burdens. Safe and effective medications for IBD prevention and treatment are urgently needed. SNX10 has emerged as a potential therapeutic target, while traditional Chinese medicine (TCM) active compounds offer unique advantages in drug development due to their inherent safety and therapeutic properties. This study aimed to identify TCM compounds targeting SNX10 using molecular docking, molecular dynamics (MD) and MMGBSA binding free energy calculations. From a pool of 300 + TCM compounds, vitexin‐4″‐O‐glucoside, scutellarin, diosmin and alpha‐hederin were identified as promising candidates. Alpha‐hederin exhibited the strongest binding affinity (−50.19 kJ/mol) via robust electrostatic and hydrophobic interactions, as revealed by MMGBSA, correlating with its superior efficacy in alleviating DSS‐induced IBD in mice. Additionally, surface plasmon resonance (SPR) results showed that alpha‐hederin can directly bind to SNX10 with a dissociation constant (Kd) of 3.02 μM. RNA‐sequencing results show that alpha‐hederin works by reducing inflammation and promoting gut cell proliferation. These findings not only propose novel TCM candidates for IBD management but also reinforce SNX10 as a therapeutic target and provide a scalable screening framework for TCM‐based drug discovery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Xi'an People's Hospital (Xi'an Fourth Hospital), School of Life Sciences and Medicine, Northwest University, Xi'an, China.
- Department of Pharmacy, Xi'an People's Hospital (Xi'an Fourth Hospital), Northwest University Affiliated People's Hospital, Xi'an, Shaanxi, China.
- Department of Pharmacology, School of Basic Medical Sciences, Peking University Health Science Center, Peking University, Beijing, China.
- Rehabilitation Industry Institute, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, China.
- School of Food Science and Technology, Jiangnan University, Wuxi, China.
ORCID-Profile: Yongpan An
Förderung
- Youth Cultivation Program of Xi'an Municipal Healthcare Commission
- Research Incubation Fund of Xi'an People's Hospital (Xi'an Fourth Hospital)
- General Research Program of Xi'an Municipal Health Commission
- Youth Program of Basic Research in Natural Sciences of Shaanxi Province
- Key Project of Basic Research in Natural Sciences of Shaanxi Province
Zitieren
APA
An, Y., Zhang, B., Ye, Y., Wang, X., Zhang, C., Ding, J., Gao, K., Ouyang, Y., Li, R., Ying, Y., Xue, X., & Wu, G. (2025). Computer‐Assisted Screening of Active Compounds in Traditional Chinese Medicine Targeting SNX10 as a Promising Treatment for Inflammatory Bowel Diseases. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.70098
Vancouver
An Y, Zhang B, Ye Y, Wang X, Zhang C, Ding J, et al. Computer‐Assisted Screening of Active Compounds in Traditional Chinese Medicine Targeting SNX10 as a Promising Treatment for Inflammatory Bowel Diseases. Basic & Clinical Pharmacology & Toxicology. 2025. doi:10.1111/bcpt.70098
BibTeX
@article{An2025,
author = {An, Yongpan and Zhang, Bowen and Ye, Yuwei and Wang, Xianghong and Zhang, Chi and Ding, Jianjun and Gao, Ke and Ouyang, Yanan and Li, Ruixiao and Ying, Yi and Xue, Xiaorong and Wu, Guojun},
title = {Computer‐Assisted Screening of Active Compounds in Traditional Chinese Medicine Targeting SNX10 as a Promising Treatment for Inflammatory Bowel Diseases},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2025},
doi = {10.1111/bcpt.70098}
}
EUVIMED